Clinical trials: Recurrence Hepatocellular Carcinoma
Carcinoma, Hepatocellular
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are…
- Trial name
- IMbrave050 (NCT04102098)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 134 sites in United States, Australia and 24 more
- Volunteers
- 668 people
- Sponsor
- Hoffmann-La Roche
Liver Cancer
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00058487
- Testing
- epirubicin hydrochloride, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma
Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation
The aim was to investigate the efficacy of radiofrequency ablation (RFA) with a multiple-electrode switching system (MESS) in the treatment of early hepatocellular carcinoma (HCC) and to evaluate the patterns and risk factors of…
- Trial name
- NCT02046356
- Testing
- MESS-RFA
- Where
- China
- Volunteers
- 139 people
- Sponsor
- Yunhua Tan
Liver Cancer
Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer
RATIONALE: Iodine I 131 ethiodized oil may help prevent or delay the recurrence of cancer. It is not yet known whether iodine I 131 ethiodized oil is more effective than non-radiolabeled ethiodized oil in preventing recurrent…
- Trial name
- NCT00870558
- Testing
- ethiodized oil, iodine I 131 ethiodized oil
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Liver Cancer
Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
RATIONALE: Octreotide may stop or slow the growth of tumor cells and may be an effective treatment for liver cancer. PURPOSE: This phase II trial is studying how well octreotide works in treating patients with locally advanced or…
- Trial name
- NCT00257426
- Testing
- octreotide acetate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC
Hepatocellular carcinoma (HCC) recurs in up to 60% of patients who undergo resection. Circulating tumor cells (CTC) have been advocated as promotors of the recurrence.
- Conditions
- Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Circulating Tumor Cell
- Trial name
- NCT04800497
- Testing
- Hepatic resection
- Where
- 4 sites in Italy
- Volunteers
- 70 people
- Sponsor
- University of Milano Bicocca
Liver Cancer
Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot…
- Trial name
- NCT00039078
- Testing
- yttrium Y 90 glass microspheres
- Where
- United States
- Sponsor
- Allan Tsung
Esophageal Cancer, Extrahepatic Bile Duct Cancer
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT00021047
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- 3 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
HCC
Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma
Radiofrequency ablation is a popular treatment for recurrent hepatocellular carcinoma (HCC),but still has a higher recurrence. Sorafenib as neo-adjuvant therapy in combination of RFA was not reported yet.
- Trial name
- ESCALATOR (NCT03097848)
- Testing
- RFA, Sorafenib
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Southwest Hospital, China
Recurrent Hepatocellular Carcinoma, Microwave Ablation
Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma
The prognosis of small liver cancer (≤5 cm) who had underwent stereotactic body radiotherapy (SBRT) is encouraging, with the 1-year local control rate has been reported to be 95-100%, 3-year local control rate about 91%, 3-year…
- Conditions
- Recurrent Hepatocellular Carcinoma, Microwave Ablation, Stereotactic Body Radiotherapy
- Trial name
- NCT03609268
- Testing
- microwave ablation (MWA), stereotactic body radiotherapy (SBRT)
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma Recurrent, Liver Transplant; Complications
Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
Objective of Study: This study will evaluate the heterogeneity and evolution pathway between primary HCC and tumor relapse after liver transplant.
- Trial name
- HELP-2020 (NCT04506398)
- Testing
- liver transplant, ctDNA, whole exome sequencing
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
HCC - Hepatocellular Carcinoma, Adjuvant Treatment
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
Evaluation of the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment of HCC with high-risk recurrence risk
- Trial name
- NCT06958484
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab
- Volunteers
- 60 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Hepatocellular Carcinoma
Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for HCC
Short-term outcomes of laparoscopic liver resection is better than those of open liver resection Laparoscopic liver resection is better than open resection in immunological aspects
- Trial name
- HCC (NCT00606385)
- Testing
- Liver resection
- Where
- South Korea
- Volunteers
- 84 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
Hepatocellular carcinoma (HCC) often has a poor prognosis after curative treatment due to frequent recurrence. Post-surgery, 60-70% of HCC patients experience recurrence, rising to 80% after ablation therapy.
- Trial name
- NCT06537193
- Testing
- AMRI, CT
- Where
- South Korea
- Volunteers
- 455 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma
Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma
In this study, safety and effects of IPM001 vaccine on human hepatocellular carcinoma are going to be investigated, IPM001 is a neoantigen/tumor-specific antigen sensitized autoimmune cell injection
- Trial name
- NCT05105815
- Testing
- IPM001
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Huashan Hospital
Hepatocellular Carcinoma, Liver Cirrhosis
Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)
Results of liver transplantation, the best theoretical treatment for HCC, are limited by tumor recurrence. In order to limit this risk Milan criteria was proposed in 1996.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Evidence of Liver Transplantation
- Trial name
- EFAPRE (NCT01198704)
- Testing
- search of factors predicting tumor recurrence
- Where
- France
- Volunteers
- 372 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma
Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation
High-risk patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) suffer from a high ratio of recurrence after liver transplantation (LT).
- Trial name
- NCT04415567
- Testing
- Lenvatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jinyang Gu
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
This phase II trial studies how well giving sunitinib malate together with capecitabine works in treating patients with unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00787787
- Testing
- sunitinib malate, capecitabine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington